Cystic fibrosis affects people of every racial and ethnic group. Of the nearly 40,000 people living with CF in the U.S., approximately 15% are identified as racially or ethnically diverse. Research shows that people of color with CF, particularly people who are Black and Hispanic, experience unique challenges and often have negative experiences that can lead to poorer outcomes. Some of these inequities are referenced in the following data.
Site Search
Although adults with cystic fibrosis are at a significantly higher risk of developing colorectal cancer than the general population, colonoscopy screening is an effective way to prevent and treat colorectal cancer by helping to detect and remove polyps. People with CF should be screened starting at age 40 (or 30 for those who have had a transplant). Find out how early screening can help reduce the risk.
When Rickey Powell’s first child, Miles, was born, he never anticipated that Miles would spend nearly a month in the NICU. Miles was not gaining weight and, after several long weeks, was diagnosed with cystic fibrosis. Two years later, Rickey’s second child, Marley, was born. She, too, was born with CF.
Pancreatic insufficiency (PI) remains a significant issue for the majority of individuals with cystic fibrosis. Recommendations include target doses of pancreatic enzyme replacement therapy (PERT) in infants, children, and adolescents.
These guidelines present recommendations on vitamin D screening, diagnosis, supplementation and treatment in children and adults with cystic fibrosis.
Airway clearance therapies improve the efficacy of the mucociliary escalator and elicit a cough. These guidelines reviewed and compared the various techniques and devices.
These guidelines provide recommendations to the cystic fibrosis community regarding the management of advanced cystic fibrosis lung disease (ACFLD), including reducing practice variability, improving the quality of life and survival of those with ACFLD, and identifying future research directions.
The purpose of these guidelines is to provide recommendations to the CF community regarding appropriate identification and timely referral of individuals with advanced CF lung disease to transplant centers.
Hemoptysis and pneumothorax are complications reported in people with cystic fibrosis. This document reflects the Cystic Fibrosis Foundation's Pulmonary Therapies Committee recommendations for the treatment of hemoptysis and pneumothorax.
Pulmonary exacerbations are common among people with cystic fibrosis, yet little is known about best treatment practices. These guidelines were developed by consensus based on expert opinion and a review of the medical literature.